{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Status:
Investigational
Source:
NCT00543816: Phase 3 Interventional Terminated Diabetes Mellitus, Type 2
(2003)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
MK-0767 is a potent hypoglycaemic insulin sensitizer being evaluated by Kyorin with potential as an antidiabetic agent. MK-0767 acts as a dual agonist of the peroxisome proliferator-activated receptors alpha and gamma, induced high-affinity interactions of PPARα and PPARγ with the transcriptional coactivator CBP in vitro. In ob/ob mice, MK-0767 normalized hyperglycemia and hyperinsulinemia with equal or greater potency and efficacy than pioglitazone. Treatment of hamsters with MK-0767 produced substantial reductions in blood cholesterol and triglycerides. In dogs, MK-0767 reduced serum cholesterol levels with a potency more than 10-fold greater than simvastatin. The efficacies of MK-0767 and simvastatin were additive when given together.
Status:
Investigational
Source:
NCT01091116: Phase 2 Interventional Completed Osteoarthritis, Knee
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Fasitibant (MEN-16132) is a non-peptide sulfonamide-containing bradykinin hB2 receptor antagonist. It inhibits pro-inflammatory response in vitro and alleviates inflammatory hyperalgesia in rodent models of osteoarthritis. Menarini Group was developing fasitibant for the treatment of osteoarthritis. Fasitibant development has been discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Forasartan (also known as SC-52458) was developed as an orally active, competitive angiotensin (Ang) II subtype 1 (AT1)-receptor antagonist for the treatment of hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. It is known that angiotensin II is a vasoconstrictor and stimulates the synthesis and release of aldosterone, and blockage of its effects results in a decrease in systemic vascular resistance. Information about the further development of forasartan is not available.
Status:
Investigational
Source:
NCT00156156: Phase 3 Interventional Completed Fibroid Uterus
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Asoprisnil (J867) is a novel selective steroid receptor modulator that shows unique pharmacodynamic effects in animal models and humans. Asoprisnil, its major metabolite J912, and other structurally related compounds represent a new class of progesterone receptor (PR) ligands that exhibit partial agonist and antagonist activities in vivo. Asoprisnil demonstrates a high degree of receptor and tissue selectivity, with a high-binding affinity for PR, moderate affinity for glucocorticoid receptor (GR), low affinity for androgen receptor (AR), and no binding affinity for estrogen or mineralocorticoid receptors. This compound was recently in clinical trials for the treatment of uterine fibroids and endometriosis, but those studies were discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Metamfazone exerts analgesic and antirheumatic activities.
Class (Stereo):
CHEMICAL (RACEMIC)
Tetriprofen is a hydratropic acid derivative patented by Swiss chemical company CIBA Ltd as an antinociceptive and anti-inflammatory agent.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Lotifazole (F 1686) - 4-phenyl-2-(2',2',2-trichloroethoxycarboxamido) thiazole is an immunostimulant. It has a range of anti-inflammatory activities in animals that differs from the activities of classic non-steroidal drugs.
Class (Stereo):
CHEMICAL (RACEMIC)
Sunagrel is a phenylethanolamine derivative patented by Maggioni Farmaceutici S.p.A. as platelet aggregation inhibitor and antilipidaemic agent.
Status:
Investigational
Source:
NCT00048659: Phase 2 Interventional Terminated Hormone-Refractory Prostate Cancer
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00132769: Phase 2 Interventional Completed Rheumatoid Arthritis
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
MK-0873 is a novel selective phosphodiesterase-4 inhibitor, which has been in development for the treatment of chronic obstructive pulmonary disease (COPD). In preclinical studies, intravenous administration of MK-0873 produced potent, dose-dependent inhibition of antigen-induced bronchoconstriction in sensitized guinea pigs. MK-0873 protected against both the early- and late-phase bronchoconstrictor response to antigen challenge in Ascaris-sensitive sheep. In healthy volunteers, MK-0873 has been shown to be safe and generally well tolerated in single oral doses up to 6 mg and in multiple oral doses up to 4 mg for 28 days. The most commonly reported adverse events were similar to those reported in other studies with drugs in its class: i.e. headaches and gastrointestinal complaints.
